- Home
- BIIB vs PSTG Comparison
BIIB vs PSTG Comparison
Compare BIIB & PSTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- PSTG
- Stock Information
- Founded
- BIIB 1978
- PSTG 2009
- Country
- BIIB United States
- PSTG United States
- Employees
- BIIB N/A
- PSTG N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- PSTG Electronic Components
- Sector
- BIIB Health Care
- PSTG Technology
- Exchange
- BIIB Nasdaq
- PSTG Nasdaq
- Market Cap
- BIIB 18.8B
- PSTG 17.4B
- IPO Year
- BIIB 1991
- PSTG 2015
- Fundamental
- Price
- BIIB $124.99
- PSTG $58.13
- Analyst Decision
- BIIB Buy
- PSTG Buy
- Analyst Count
- BIIB 27
- PSTG 18
- Target Price
- BIIB $188.17
- PSTG $69.39
- AVG Volume (30 Days)
- BIIB 1.2M
- PSTG 2.5M
- Earning Date
- BIIB 07-31-2025
- PSTG 08-27-2025
- Dividend Yield
- BIIB N/A
- PSTG N/A
- EPS Growth
- BIIB 26.39
- PSTG 32.17
- EPS
- BIIB 10.12
- PSTG 0.37
- Revenue
- BIIB $9,816,400,000.00
- PSTG $3,253,170,000.00
- Revenue This Year
- BIIB N/A
- PSTG $13.31
- Revenue Next Year
- BIIB N/A
- PSTG $13.68
- P/E Ratio
- BIIB $12.35
- PSTG $157.00
- Revenue Growth
- BIIB 1.59
- PSTG 10.85
- 52 Week Low
- BIIB $110.04
- PSTG $34.51
- 52 Week High
- BIIB $236.48
- PSTG $73.67
- Technical
- Relative Strength Index (RSI)
- BIIB 41.14
- PSTG 60.31
- Support Level
- BIIB $132.37
- PSTG $53.43
- Resistance Level
- BIIB $137.84
- PSTG $59.31
- Average True Range (ATR)
- BIIB 4.16
- PSTG 1.74
- MACD
- BIIB -0.68
- PSTG -0.01
- Stochastic Oscillator
- BIIB 7.82
- PSTG 79.96
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About PSTG Pure Storage Inc.
Pure Storage Inc is a U.S.-based company that provides an enterprise data storage platform that transforms business through a dramatic increase in performance and reduction in complexity and costs. It generates revenue from two sources: product revenue, which includes the sale of integrated storage hardware and embedded operating system software; and subscription services revenue, which includes Evergreen Storage subscriptions, a unified subscription that includes Pure as-a-Service, Cloud Block Store, and Portworx. Subscription services revenue also includes professional services offerings such as installation and implementation consulting services.